Your browser doesn't support javascript.
loading
Ex vivo γH2AX assay for tumor radiosensitivity in primary prostate cancer patients and correlation with clinical parameters.
Marinescu, Ioana M; Rogg, Manuel; Spohn, Simon; von Büren, Moritz; Kamps, Marius; Jilg, Cordula A; Fountzila, Elena; Papadopoulou, Kyriaki; Ceci, Lara; Bettermann, Alisa; Ruf, Juri; Benndorf, Matthias; Adebahr, Sonja; Zips, Daniel; Grosu, Anca L; Schell, Christoph; Zamboglou, Constantinos.
Afiliación
  • Marinescu IM; Department of Radiation Oncology, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany. maria.marinescu@uniklinik-freiburg.de.
  • Rogg M; German Cancer Consortium (DKTK), Partner Site, Freiburg, Germany. maria.marinescu@uniklinik-freiburg.de.
  • Spohn S; Institute for Surgical Pathology, Medical Center - University of Freiburg, Freiburg, Germany.
  • von Büren M; Department of Radiation Oncology, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany.
  • Kamps M; German Cancer Consortium (DKTK), Partner Site, Freiburg, Germany.
  • Jilg CA; Department of Urology, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany.
  • Fountzila E; Department of Urology, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany.
  • Papadopoulou K; Department of Urology, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany.
  • Ceci L; Second Department of Medical Oncology, Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece.
  • Bettermann A; Greece and European University Cyprus, Engomi, Cyprus.
  • Ruf J; Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Benndorf M; Department of Radiation Oncology, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany.
  • Adebahr S; German Cancer Consortium (DKTK), Partner Site, Freiburg, Germany.
  • Zips D; Department of Radiation Oncology, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany.
  • Grosu AL; German Cancer Consortium (DKTK), Partner Site, Freiburg, Germany.
  • Schell C; Department of Nuclear Medicine, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany.
  • Zamboglou C; Department of Radiology, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany.
Radiat Oncol ; 17(1): 163, 2022 Oct 05.
Article en En | MEDLINE | ID: mdl-36199143
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Antígeno Prostático Específico Tipo de estudio: Prognostic_studies Límite: Humans / Male Idioma: En Revista: Radiat Oncol Asunto de la revista: NEOPLASIAS / RADIOTERAPIA Año: 2022 Tipo del documento: Article País de afiliación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Antígeno Prostático Específico Tipo de estudio: Prognostic_studies Límite: Humans / Male Idioma: En Revista: Radiat Oncol Asunto de la revista: NEOPLASIAS / RADIOTERAPIA Año: 2022 Tipo del documento: Article País de afiliación: Alemania